ClinicalTrials.Veeva

Menu

Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer

B

Beijing GoBroad Hospital

Status and phase

Not yet enrolling
Phase 2

Conditions

Advanced Breast Cancer

Treatments

Drug: Adebrelimab
Drug: SHR-A1921
Drug: SHR-A1811

Study type

Interventional

Funder types

Other

Identifiers

NCT06433609
BJGBYY-IIT-LCYJ-2024-008
BC-MUL-IIT-ADC-SHR1316 (Other Identifier)

Details and patient eligibility

About

Our study is aimed to evaluate the efficacy and safety of novel ADCs named SHR-A1811 and SHR-A1921 combined with adebrelimab in HER2-negative advanced breast cancer.

Enrollment

131 estimated patients

Sex

Female

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. 18 years to 75 years old (including boundary values), female patients with breast cancer;
  2. ECOG PS Score: 0~1;
  3. Histologically or cytologically confirmed HER2-negative advanced breast cancer;
  4. Disease progression after prior 1-2 lines of systemic therapy; if HR-positive, prior CDK4/6 inhibitor is necessary;
  5. Based on RECIST v1.1, at least one measurable lesion;
  6. Brain metastasis with no clinical symptoms, or treated, stable brain metastases are eligible;
  7. No prior PD-(L)1 inhibitor;
  8. Patients must have a life expectancy ≥ 6 months;
  9. Adequate organ function and marrow function (no corrective treatment within 14 days before first dose);
  10. Patients of childbearing potential should have a negative urine or serum pregnancy, and must promise to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study therapy or be celibate;
  11. Available blood samples for ctDNA detection in the exploratory study;
  12. Willing and able to provide written informed consent and comply with the requirements and restrictions in the protocol.

Exclusion criteria

  1. Has known active brain metastasis which needs local therapy immediately;
  2. Prior anti-HER2 or anti-TROP-2 treatment;
  3. Has received or been receiving PD-(L)1 inhibitors and/or ADC containing a topoisomerase inhibitor-like payload;
  4. Existence of third space fluid that is not well controlled by effective methods, e.g. drainage;
  5. Has received antitumor surgery, radiotherapy, chemotherapy, targeted therapy or immunological therapy within 4 weeks before first dose of study therapy; has received antitumor endocrine therapy within one week before first dose of study therapy;
  6. Use of other antitumor systemic treatment during the study;
  7. Has active autoimmune disease or a history of autoimmune disease;
  8. Known history of immunodeficiency, including HIV-positive, other acquired or innate immunodeficient disease, or known history of organ transplantation;
  9. Has active hepatitis B (HBsAg-positive and HBV DNA≥500 IU/mL), hepatitis C (positive for HCV antibody and HCV RNA above ULN) and hepatic cirrhosis;
  10. Has an active infection requiring antibiotics, antiviral or antifungal treatment, or pyrexia >38.5℃ of unknown origin during the screening period before first dose of study therapy (patients with pyrexia due to cancer could be enrolled determined by investigator);
  11. Receiving immunosuppressive medication, or systemic corticosteroid therapy for the purpose of immunosuppression (prednisone at >10mg/d or equivalent dose of other corticosteroids), and continuous use within 2 weeks before the first dose of study therapy;
  12. Other malignancy within prior 5 years unless curatively treated with no evidence of disease for at least recent 3 years, except: curatively treated in situ cancer of the cervix, skin basal cell carcinoma or skin squamous cell carcinoma;
  13. Hypersensitivity to study therapy or any of its excipients;
  14. Has known clinically significant lung disease, including but not limited to: interstitial lung disease, pneumonitis, pulmonary fibrosis;
  15. Known history of uncontrolled cardiovascular clinical symptom or disease that is not well controlled;
  16. Has received a live vaccine within 4 weeks before first dose of study therapy, or potential to receive a live vaccine during the trial treatment;
  17. Patients with a positive serum or urine pregnancy test or who are breastfeeding; patients of childbearing potential who are unwilling or not available to use an effective method of contraception;
  18. Other conditions that might influence the study and analysis of results in the opinion of the investigator.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

131 participants in 2 patient groups

SHR-A1811+adebrelimab
Experimental group
Treatment:
Drug: SHR-A1811
Drug: Adebrelimab
SHR-A1921+adebrelimab
Experimental group
Treatment:
Drug: SHR-A1921
Drug: Adebrelimab

Trial contacts and locations

1

Loading...

Central trial contact

Yang Ke

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems